Biotech News
Related news
CORTCorcept2026-04-10 20:45 EST
Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
CORTCorcept2026-10-26 12:00 EST
Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer
VKTXViking Therapeutics2026-10-14 11:05 EST
Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity
VKTXViking Therapeutics2026-10-06 11:05 EST
Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity
NBIXNeurocrine Biosciences2026-07-01 20:05 EST
Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia
NBIXNeurocrine Biosciences2026-08-07 12:30 EST
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist
CRNXCrinetics Pharmaceuticals2026-01-04 21:00 EST
Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia
CRNXCrinetics Pharmaceuticals2026-01-22 21:05 EST
Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)
Corcept
Cortisol Modulation Platform Corcept Therapeutics develops medicines that selectively modulate the glucocorticoid receptor and the effects of cortisol. Its portfolio spans endocrinology, oncology, metabolism and neurology. Cushing’s Syndrome Franchise Corcept has an established commercial business treating hypercortisolism in patients...
Recent company news
CORTCorcept2026-11-03 21:05 EST
Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
CORTCorcept2026-10-27 20:05 EST
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
CORTCorcept2026-10-26 12:00 EST
Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer
CORTCorcept2026-10-20 20:00 EST
2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes
CORTCorcept2026-09-23 12:00 EST
Corcept Announces Planned Leadership Transition
Stock data
- Close
- 71.63 USD
- Market cap
- 7.64B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States